Bromodeoxyuridine/BrdU Antibody (MoBu-1) [DyLight 650]

• Reactivity: All-NA
• Applications: Flow, ICC/IF, IHC, CyTOF-ready
• Clone: MoBu-1
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: DyLight 650

Bromodeoxyuridine/BrdU Antibody (MoBu-1) [DyLight 650] Summary

• Immunogen: Bromodeoxyuridine/BrdU conjugated to hemocyanine (isolated from Helix pomatia)
• Specificity: It reacts with Bromodeoxyuridine (BrdU) in single stranded DNA (produced by partial denaturation of double stranded DNA), BrdU coupled to a protein carrier, as well as free BrdU. BrdU is a thymidine analog, incorporated into cell nuclei during DNA synthesis prior to mitosis. Antibody to BrdU is helpful in detecting S-phase cells, providing useful information on the aggressiveness of tumors.
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry
  • Immunocytochemistry/ Immunofluorescence
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Reactivity Notes

Human reactivity reported in scientific literature (PMID: 26067754).

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Protein A or G purified

Notes

DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

Alternate Names for Bromodeoxyuridine/BrdU Antibody (MoBu-1) [DyLight 650]

• 5-bromo-2-deoxyuridine
• BrdU
• Bromodeoxyuridine
• BUdr

Background

Bromodeoxyuridine (BrdU) is a synthetic nucleoside analogue of thymidine which can be incorporated into DNA in proliferating cells. During mitosis, BrdU may be incorporated into the newly synthezised DNA of S-phase cells, and can therefore provide an estimate for the fraction of cells in S-phase. Labeling cells with BrdU and then screening with BrdU antibodies has become a powerful tool to study the cytokinetics of normal and neoplastic cells. In vivo, BrdU is considered a potential carcinogen, as its incorporation into DNA may cause mutations.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

FAQs for Bromodeoxyuridine/BrdU Antibody (NBP2-68041C). (Showing 1 - 1 of 1 FAQ).

1. I have been using your BrdU antibody for some time now and saw that you have discontinued it. I was wondering if you had any alternative antibodies that would also work? it is antibody NB500-169 lot# 1706-5
   • We recommend this product: NB500-235​